Trending...
- Proper Sky Named to the 2026 MSP 501
- Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
- New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026
PHILADELPHIA, April 14, 2025 ~ A team of researchers at Children's Hospital of Philadelphia (CHOP) has made a significant breakthrough in the understanding of neuroblastoma, a common and potentially deadly childhood cancer. Led by senior study author Kai Tan, PhD, the team developed a longitudinal atlas of neuroblastoma to gain deeper insights into the molecular mechanisms underlying treatment resistance.
Published in the journal Nature Genetics, the study offers valuable new insights that could potentially lead to personalized medicine approaches in neuroblastoma treatment. Despite significant advances in standard care, the 5-year survival rate for high-risk neuroblastoma remains less than 50%. One of the major challenges in treating this cancer is its heterogeneity, with different cells within the same tumor exhibiting varying characteristics.
The lack of understanding about how these cells interact and change during treatment has been a major barrier in developing effective therapies. In this study, researchers created a cell atlas that provided an in-depth look at how different cell types, such as malignant cells and immune cells, interact and change within their natural environment.
More on The PennZone
"Our atlas provides a crucial foundation for developing novel treatments by mapping the complex interactions between malignant cells and surrounding cells that support tumor growth," said Dr. Tan. "As researchers, we look to use these insights to tailor therapies to target unique characteristics of a patient's tumor. Overall, we are optimistic about the doors our research and techniques are opening."
To create this atlas, CHOP researchers used advanced single-cell sequencing and spatial omics techniques to analyze tumor samples from 22 pediatric patients with high-risk neuroblastoma before and after chemotherapy. This multidimensional dataset is now available on the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN) data portal.
The team uncovered diverse characteristics of both tumor and non-tumor cells, as well as major changes in these characteristics following chemotherapy. They found that patients had worse outcomes when cancer cells were multiplying more actively and became more metabolically active. On the other hand, tumors that developed more mature, neuron-like features resulted in better outcomes for patients.
Additionally, the researchers found that an increase in a type of mesenchymal-like tumor cells was linked to poorer responses to chemotherapy. They also discovered that certain immune cells, such as macrophages, became more active in ways that promoted tumor growth by enabling blood vessel growth while suppressing the immune response.
More on The PennZone
One of the most significant findings of the study was a specific communication pathway between macrophages and cancer cells (HB-EGF/ERBB4) that triggered signals promoting tumor growth. This highlights the importance of identifying new factors within the tumor microenvironment that influence treatment response. The team is now conducting further studies using preclinical models to test this pathway and potentially develop novel therapeutic strategies.
"This study would not have been possible without the monumental team efforts of biologists, clinicians, and computational scientists," said lead author Wenbao Yu, PhD. "With their collaboration, we were able to gain new insights into the complex ecosystem of neuroblastoma."
The research was supported by a grant from the National Cancer Institute (NCI) Human Tumor Atlas Network (#U2C CA233285), as well as grants from the National Institutes of Health (NIH) (U54 HL165442), American Cancer Society Institutional Research Grant (IRG-22-150-41-IRG), and NIH (T32 CA009140).
This groundbreaking study, titled "Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring," was published online on April 14th, 2025 in Nature Genetics. The DOI for this article is 10.1038/s41588-025-02158-6.
Published in the journal Nature Genetics, the study offers valuable new insights that could potentially lead to personalized medicine approaches in neuroblastoma treatment. Despite significant advances in standard care, the 5-year survival rate for high-risk neuroblastoma remains less than 50%. One of the major challenges in treating this cancer is its heterogeneity, with different cells within the same tumor exhibiting varying characteristics.
The lack of understanding about how these cells interact and change during treatment has been a major barrier in developing effective therapies. In this study, researchers created a cell atlas that provided an in-depth look at how different cell types, such as malignant cells and immune cells, interact and change within their natural environment.
More on The PennZone
- PropAccount.com Adds Prediction Markets to Its Multi-Asset Prop Firm Platform
- ToyLookup.com Launches AI-Powered Platform to Help Collectors Identify Vintage and Modern Toys
- Rising star Hip-Hop and R&B Force Della Drops Highly Anticipated New Single, "Throw It"
- UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch
- From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
"Our atlas provides a crucial foundation for developing novel treatments by mapping the complex interactions between malignant cells and surrounding cells that support tumor growth," said Dr. Tan. "As researchers, we look to use these insights to tailor therapies to target unique characteristics of a patient's tumor. Overall, we are optimistic about the doors our research and techniques are opening."
To create this atlas, CHOP researchers used advanced single-cell sequencing and spatial omics techniques to analyze tumor samples from 22 pediatric patients with high-risk neuroblastoma before and after chemotherapy. This multidimensional dataset is now available on the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN) data portal.
The team uncovered diverse characteristics of both tumor and non-tumor cells, as well as major changes in these characteristics following chemotherapy. They found that patients had worse outcomes when cancer cells were multiplying more actively and became more metabolically active. On the other hand, tumors that developed more mature, neuron-like features resulted in better outcomes for patients.
Additionally, the researchers found that an increase in a type of mesenchymal-like tumor cells was linked to poorer responses to chemotherapy. They also discovered that certain immune cells, such as macrophages, became more active in ways that promoted tumor growth by enabling blood vessel growth while suppressing the immune response.
More on The PennZone
- Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
- June Employment Report Reveals Hidden Weakness Beneath Lower Unemployment
- Exeter Smiles Encourages Families to Start Teen Braces This Summer
- The Hue Society Expands Roster for the 2026 Wine and Culture Fest
- Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
One of the most significant findings of the study was a specific communication pathway between macrophages and cancer cells (HB-EGF/ERBB4) that triggered signals promoting tumor growth. This highlights the importance of identifying new factors within the tumor microenvironment that influence treatment response. The team is now conducting further studies using preclinical models to test this pathway and potentially develop novel therapeutic strategies.
"This study would not have been possible without the monumental team efforts of biologists, clinicians, and computational scientists," said lead author Wenbao Yu, PhD. "With their collaboration, we were able to gain new insights into the complex ecosystem of neuroblastoma."
The research was supported by a grant from the National Cancer Institute (NCI) Human Tumor Atlas Network (#U2C CA233285), as well as grants from the National Institutes of Health (NIH) (U54 HL165442), American Cancer Society Institutional Research Grant (IRG-22-150-41-IRG), and NIH (T32 CA009140).
This groundbreaking study, titled "Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring," was published online on April 14th, 2025 in Nature Genetics. The DOI for this article is 10.1038/s41588-025-02158-6.
Filed Under: Business
0 Comments
Latest on The PennZone
- Former MP Shri GV Harsha Kumar Meets AICC President Mallikarjun Kharge
- Two Attorneys at The Stanley Law Group Named to 2026 South Carolina Super Lawyers List
- IGH Naturals Announces Peer-Reviewed HuMOLYTE® Study Published in Frontiers in Nutrition
- LINC to Host CEO Breakfast Forum on July 22
- The Explorer Shaped Guitar Still a Symbol of Heavy Music with New Releases
- Allstream Energy Partners Expands AI-Optimized Website Development Division to Meet Growing Demand in GEO / AEO Services
- Nola Blue announces 'Jumpin' Rockin Rhythm,' the autobiography of Duke Robillard
- America's Workforce Solution Named an OpenAI SMB Channel Partner, Bringing Enterprise-Grade AI to Main Street
- Data Tiles Introduces the Decision-Driven Enterprise to North America
- Disruptor Creations Pioneers New MicroAdventure Series with TravelSpike
- Hawk Hill Pictures Brings Ukrainian-Language War Drama BUCHA to North American Audiences
- eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
- Creative Investment Research Welcomes Supreme Court Decision Protecting Federal Reserve Independence While Calling for Continued Accountability
- Rebecca Francis Team Ranks Among Top 1.5% of Teams and Agents Nationwide
- Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
- Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Morrisville & Cary Education Centers Honored with National Award
- AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
- Henri-Lloyd Launches Sail Free to Break Down Barriers to Sailing
- Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park